We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+81.75%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$99.4M
AUM Growth
-$24.1M
Cap. Flow
-$19.6M
Cap. Flow %
-19.71%
Top 10 Hldgs %
60.37%
Holding
49
New
8
Increased
12
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
DRUG
Bright Minds Biosciences
DRUG
+$2.43M
2
TRVI icon
Trevi Therapeutics
TRVI
+$1.54M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.35M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$1.06M
5
ZYME icon
Zymeworks
ZYME
+$940K

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$8.98M
2
ACLX
Arcellx
ACLX
+$4.44M
3
KURA icon
Kura Oncology
KURA
+$3.85M
4
TSHA icon
Taysha Gene Therapies
TSHA
+$2.56M
5
CMPS
Compass Pathways
CMPS
+$2.43M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$1.84B
$9.49M 9.55%
1,111,071
-79,000
-7% -$771K
INSM icon
2
Insmed
INSM
$21.3B
$7.24M 7.28%
104,800
-2,700
-3% -$194K
TRML
3
DELISTED
Tourmaline Bio
TRML
$7.14M 7.18%
351,842
+19,747
+6% +$497K
CRNX icon
4
Crinetics Pharmaceuticals
CRNX
$8.87B
$6.28M 6.32%
122,900
-8,800
-7% -$492K
ELVN icon
5
Enliven Therapeutics
ELVN
$4.15B
$6.02M 6.05%
267,368
-29,000
-10% -$752K
WHWK
6
Whitehawk Therapeutics
WHWK
$196M
$5.83M 5.87%
1,849,402
– –
PRAX icon
7
Praxis Precision Medicines
PRAX
$8.52B
$5.19M 5.23%
67,500
+10,000
+17% +$724K
RVMD icon
8
Revolution Medicines
RVMD
$38.8B
$4.89M 4.92%
111,700
+3,700
+3% +$187K
ARGX icon
9
argenx
ARGX
$52B
$4.25M 4.28%
6,910
+1,010
+17% +$592K
PCVX icon
10
Vaxcyte
PCVX
$7.73B
$3.68M 3.71%
45,000
-90,400
-67% -$8.98M
TRVI icon
11
Trevi Therapeutics
TRVI
$2.54B
$3.18M 3.2%
771,958
+481,458
+166% +$1.54M
ASND icon
12
Ascendis Pharma A/S
ASND
$16B
$3.16M 3.18%
22,976
+1,976
+9% +$260K
MREO
13
Mereo BioPharma
MREO
$50.4M
$2.73M 2.74%
779,308
-481,392
-38% -$1.89M
DRUG
14
Bright Minds Biosciences
DRUG
$724M
$2.49M 2.5%
+69,124
New +$2.43M
TERN
15
DELISTED
Terns Pharmaceuticals
TERN
$2.48M 2.49%
447,500
-39,500
-8% -$267K
EWTX icon
16
Edgewise Therapeutics
EWTX
$4.13B
$2.34M 2.35%
87,658
+24,658
+39% +$785K
BBOT
17
BridgeBio Oncology
BBOT
$661M
$1.9M 1.91%
180,945
– –
UNCY icon
18
Unicycive Therapeutics
UNCY
$138M
$1.83M 1.84%
230,300
+32,380
+16% +$179K
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$372M
$1.69M 1.7%
134,500
-55,500
-29% -$835K
LQDA icon
20
Liquidia Corp
LQDA
$7.46B
$1.62M 1.63%
137,709
+64,209
+87% +$702K
MRSN
21
DELISTED
Mersana Therapeutics
MRSN
$1.6M 1.61%
44,820
-3,180
-7% -$165K
TSHA icon
22
Taysha Gene Therapies
TSHA
$1.66B
$1.53M 1.54%
884,244
-1,234,748
-58% -$2.56M
TECX
23
Tectonic Therapeutic
TECX
$527M
$1.52M 1.53%
33,008
+19,308
+141% +$817K
CDTX
24
DELISTED
Cidara Therapeutics
CDTX
$1.46M 1.47%
+54,473
New +$885K
NAMS icon
25
NewAmsterdam Pharma
NAMS
$3.21B
$1.28M 1.29%
+50,000
New +$1.06M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Acuta Capital Partners held 49 positions worth $99.4M, down 19% from $123M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners withdrew a net $19.6M in Q4 2024, closing 10 positions and reducing 15 holdings. Its most notable exit was Kura Oncology, an estimated $3.85M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Bright Minds Biosciences worth $2.49M.

  • Acuta Capital Partners's largest Q4 2024 buy was Bright Minds Biosciences: 69,124 shares worth $2.49M.
  • Acuta Capital Partners added most to Trevi Therapeutics in Q4 2024, an estimated $1.54M increase.
  • Acuta Capital Partners's biggest Q4 2024 reduction was Vaxcyte, cutting an estimated $8.98M.
  • Acuta Capital Partners fully exited Kura Oncology in Q4 2024, selling an estimated $3.85M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $99.4M portfolio in Q4 2024.
  • Acuta Capital Partners opened 8 new positions and closed 10 in Q4 2024.
  • Acuta Capital Partners's portfolio value fell 19% quarter-over-quarter to $99.4M.

Based on Acuta Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.